Reason Why PD-1PD-L1 inhibitor 2 Selling Price Will Be Left Somewhat High

Balancing the morbidity of over-diagnosis and over-treatment as a result of PSA-based screening with the likely modest improvement in survival remains a significant dilemma in the management of prostate cancer. ""A recent study confirms that thromboembolism (TE) is a significant risk in patients with exocrine pancreatic cancer, showing a 36% incidence as well as conferring a worse prognosis (Cancer [published online ahead of print http://www.selleckchem.com/products/gsk1120212-jtp-74057.html October 11, 2011] doi: 10.1002/cncr.26600). Andrew Epstein, MD, professor in the division of gastrointestinal medical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, and colleagues conducted a review of patients with pancreatic cancer to assess the impact and timing of TE on survival and to examine associations between other clinical variables and risk of TE. Using an institutional electronic application, investigators identified patients with pancreatic cancer who were treated with http://www.selleck.cn/products/pd-1-pd-l1-inhibitor-2.html chemotherapy at MSKCC from January 1, 2000 through December 31, 2009. Any patient records found by the electronic application to have a diagnosis code indicating TE were then manually reviewed for data. In addition, to verify the accuracy of the electronic application in selecting records relevant to this study, 50 randomly selected charts from patients with pancreatic cancer but no coded TE event were reviewed manually and none were found to have had a TE. Eight patients who were diagnosed with a TE more than 3 months before the diagnosis of pancreatic cancer were excluded from analyses. The median survival of the 1915-patient cohort was 13.7 months, and 690 patients (36%) had at least one TE recorded. Of the 690 patients with TE, 614 (89%) had a non�Ccatheter-related deep vein thrombosis and/or pulmonary embolism. An arterial TE occurred in 30 patients (4.4%). A total of 638 patients (92.5%) had locally advanced or metastatic disease when their first TE was diagnosed. After adjusting for pancreatic surgery, having a TE significantly increased the risk of death during the follow-up interval with a hazard ratio (HR) of 2.6 (P http://www.selleckchem.com/products/MDV3100.html a TE within 1.5 months from the diagnosis of pancreatic cancer had a significantly higher risk of death than patients who did not develop a TE within 1.5 months of their cancer diagnosis (HR, 2.1; P